SecBot SecBot
Biotech Drug Report Generated Oct 30, 2026

golcadomide

BMY·BRISTOL MYERS SQUIBB CO
NEUTRAL
Drug Impact Rating6/10
Trial phase
Phase 3
Time to market
At least 3-5 years away if Phase 3 trials succeed. The GOLSEEK-1 primary completion is August 2027, followed by data analysis, regulatory filing (likely 2028), and FDA review (2028-2029).
Why 6/10
The next hard catalyst is the GOLSEEK-1 Phase 3 primary completion/readout expected around August 9, 2027 (about 9.5 months from today). This is a pivotal readout on a meaningful pipeline asset, but BMY is a diversified mega-cap pharma with many approved products and pipeline programs, so this single drug does not drive most of the company's valuation.
Actionable Insight NEUTRAL

The next hard catalyst is the GOLSEEK-1 Phase 3 topline readout for golcadomide + R-CHOP in high-risk large B-cell lymphoma, with primary completion estimated around August 9, 2027. A positive readout would support a future NDA filing and position golcadomide as a potential first-in-class oral CELMoD for lymphoma. A negative or mixed result would likely end the program. For BMY, a diversified mega-cap, the stock impact would be modest relative to a single-asset biotech.

Price Chart

Loading chart...

Executive Summary

Golcadomide is Bristol Myers Squibb's (BMY) investigational oral CELMoD agent in Phase 3 testing for B-cell non-Hodgkin lymphomas (high-risk large B-cell lymphoma and relapsed/refractory follicular lymphoma). It is not yet FDA approved and no NDA has been filed. The nearest hard catalyst is the GOLSEEK-1 Phase 3 primary completion/readout expected around August 2027. BMY is a mega-cap pharma with dozens of marketed products and a deep pipeline, so golcadomide is a meaningful but not company-defining asset. Two sibling CELMoDs from BMS (iberdomide and mezigdomide) were both FDA-approved in 2026 for multiple myeloma, validating the platform but not this specific lymphoma indication.

How It Works

Golcadomide is an oral pill that works as a 'molecular glue' inside cells. It binds to a protein called cereblon, which then marks two cancer-promoting proteins (Ikaros and Aiolos) for destruction by the cell's garbage-disposal system. This kills lymphoma cells directly and also boosts the immune system's ability to fight the cancer. It is designed to concentrate in lymph tissues where lymphoma grows.

Trial Status

Two Phase 3 trials are ongoing: GOLSEEK-1 (NCT06356129) evaluating golcadomide + R-CHOP vs placebo + R-CHOP in ~850 patients with previously untreated high-risk large B-cell lymphoma (enrollment complete, active not recruiting, primary completion moved to August 9, 2027); and GOLSEEK-4 (NCT06911502) evaluating golcadomide + rituximab vs investigator's choice in relapsed/refractory follicular lymphoma (currently recruiting). Phase 1/2 data presented at ASH 2025 and ASCO 2026 showed promising efficacy with durable responses and manageable safety.

The Two-Sided Case

▲ Bull Case4
Golcadomide is a potential first-in-class oral CELMoD specifically designed for lymphoma with preferential lymphoid distribution, differentiating it from other CELMoDs. Phase 1/2 data showed an 89% overall response rate and 61% complete response rate in heavily pretreated relapsed/refractory follicular lymphoma patients (ASH 2025).
Two sibling CELMoDs from BMS (iberdomide/Zenbexus and mezigdomide/Opzykio) both received FDA accelerated approval in 2026 for multiple myeloma, validating the CELMoD platform and BMS's expertise in this drug class.
Golcadomide targets a large addressable market: non-Hodgkin lymphomas (DLBCL and FL) affect over 80,000 new patients annually in the US alone, and there is high unmet need for oral, chemotherapy-free options.
BMY has the financial resources and commercial infrastructure to maximize golcadomide's potential if approved, with existing hematology oncology sales teams.
▼ Bear Case5
Golcadomide is still in Phase 3 testing with no NDA filed; the GOLSEEK-1 readout is not expected until around August 2027, and Phase 3 trials in oncology frequently fail to replicate early-phase promise.
BMY is a mega-cap pharma ($62 stock, ~$125B market cap) with many approved blockbusters (Opdivo, Eliquis) and pipeline programs, so even a positive golcadomide readout would have limited impact on the stock price.
The CELMoD class carries boxed warnings for embryo-fetal toxicity and thromboembolic events (as seen with approved iberdomide), which could limit commercial uptake.
Competition in lymphoma is intense: approved therapies include CAR-T cells, bispecific antibodies, lenalidomide (Revlimid), and targeted agents. Golcadomide would need to demonstrate clear superiority to gain share.
Analyst sentiment on BMY is mixed: 18 hold ratings vs 15 buy/strong buy, with a mean price target of $65.25 implying only ~7.7% upside, and one downgrade in the last 90 days (Leerink from Outperform to Market Perform).

Upcoming Catalysts

  • GOLSEEK-1 Phase 3 primary completion/readout for golcadomide + R-CHOP in high-risk large B-cell lymphoma, estimated around August 9, 2027
  • GOLSEEK-4 Phase 3 enrollment updates and potential interim analyses for golcadomide + rituximab in relapsed/refractory follicular lymphoma
  • Additional data presentations at upcoming medical conferences (ASH 2026, ASCO 2027)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

BRISTOL MYERS SQUIBB CO 8-K BMY ·Originating report

Sources · 15

Hover a chip for the title
1 bmsclinicaltrials.com2 drugs.com3 news.bms.com4 ashpublications.org5 pharmaceutical-technology.com6 ashpublications.org7 ashpublications.org8 clinicaltrials.gov9 clinicaltrials.gov10 drugs.com11 fda.gov12 csa.dataengineered.io13 dashboard.datalookout.com14 news.bms.com15 news.bms.com